CDR-132L
- Generic Name
- CDR-132L
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
- First Posted Date
- 2025-05-19
- Last Posted Date
- 2025-05-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT06979375
- Locations
- 🇦🇺
Victorian Heart Hospital, Clayton, Victoria, Australia
🇦🇺Fiona Stanley Hospital Cardiology, Murdoch, Western Australia, Australia
🇨🇿Fakultnà nemocnice u sv. Anny v Brně, Brno, Czechia
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
- First Posted Date
- 2025-05-19
- Last Posted Date
- 2025-05-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT06979362
- Locations
- 🇮🇳
Sengupta Hospital and Research Institute, Nagpur, Maharashtra, India
🇺🇸Duke University_Durham, Durham, North Carolina, United States
🇺🇸Univ of Alabama Birmingham, Birmingham, Alabama, United States
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Registration Number
- NCT05953831
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
- Conditions
- Myocardial Infarction, AcuteHeart Failure, Left Sided
- Interventions
- Drug: Placebo to CDR132L
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Target Recruit Count
- 294
- Registration Number
- NCT05350969
- Locations
- 🇵🇱
Polsko Amerykanskie Kliniki Serca, Kędzierzyn-Koźle, Poland
🇵🇱NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog, Sopot, Poland
🇳🇱Deventer Ziekenhuis, Deventer, Netherlands
Clinical Study to Assess Safety, PK and PD Parameters of CDR132L
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT04045405
- Locations
- 🇬🇧
Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.